LM-108 + penpulimab + nab-paclitaxel + gemcitabine

This drug is a **combination therapy** that includes LM-108, penpulimab, nab-paclitaxel, and gemcitabine. - **LM-108**: An investigational agent with an unspecified mechanism (likely under development, further details not specified in current sources). - **Penpulimab**: A humanized monoclonal antibody (IgG1) that targets programmed cell death protein 1 (**PD-1**) to inhibit immune checkpoint pathways, stimulating antitumor immune responses[2][4]. - **Nab-paclitaxel**: A nanoparticle albumin-bound formulation of paclitaxel, a microtubule stabilizer that inhibits cell division in cancer cells, designed to avoid toxic solvent exposure and enhance drug delivery to tumor tissues[6]. - **Gemcitabine**: A nucleoside analog that disrupts DNA synthesis, leading to apoptosis in dividing cells. The combination is being investigated for **advanced solid tumors** and primarily **advanced pancreatic cancer**, aiming to leverage immune checkpoint inhibition (penpulimab), cytotoxicity through disruption of microtubules (nab-paclitaxel), nucleoside analog interference (gemcitabine), and an investigational agent (LM-108) for synergistic antitumor effects[1][4]. The regimen is currently in **Phase Ib/II clinical trials** for advanced pancreatic cancer[1][7].

Other names

albumin-bound paclitaxelpaclitaxel for injection (albumin bound)gemcitabine hydrochloride for injectionAK105 (penpulimab)